The canine as a model of human cognitive aging: Recent developments, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.24, issue.5, pp.675-692, 2000. ,
DOI : 10.1016/S0278-5846(00)00101-9
Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial A??, Neuron, vol.59, issue.1, pp.43-55, 2008. ,
DOI : 10.1016/j.neuron.2008.06.018
Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated alzheimer's disease model ? Neuroscience, pp.639-688, 2004. ,
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer???s Disease Treatment Studies, American Journal of Psychiatry, vol.159, issue.5, pp.738-783, 2002. ,
DOI : 10.1176/appi.ajp.159.5.738
Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory -DNA and cell biology, pp.737-781, 2001. ,
Unequal Neuroprotection Afforded by the Acetylcholinesterase Inhibitors Galantamine, Donepezil, and Rivastigmine in SH-SY5Y Neuroblastoma Cells: Role of Nicotinic Receptors, Journal of Pharmacology and Experimental Therapeutics, vol.315, issue.3, pp.1346-53, 2005. ,
DOI : 10.1124/jpet.105.090365
une approche historique -Découvertes scientifiques, évolutions de la société, travaux législatifs, 2000. ,
La prise en soins d'un patient atteint de la maladie d'Alzheimer, au travers de situations spécifiques -NPG Neurologie, 2008. ,
DOI : 10.1016/j.npg.2008.01.002
-Classification des démences : aspects nosologiques -Médecine Nucléaire, Juin, vol.31, issue.6, pp.278-293, 2007. ,
DOI : 10.1016/j.mednuc.2007.04.005
-Spatial navigation in the Morris water maze: working and long lasting reference memories -Neuroscience Letters, pp.176-80, 2005. ,
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood?brain barrier -Advanced Drug Delivery Reviews, pp.629-639, 2012. ,
-Résultats de l'étude Paquid 2004 -www.isped.u- bordeaux2, 2012. ,
Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nature Medicine, vol.6, issue.8, pp.916-935, 2000. ,
DOI : 10.1038/78682
-Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease ? Neurotherapeutics, pp.381-90, 2008. ,
Presymptomatic Alzheimer's disease in the Dominantly Inherited Alzheimer's Network (DIAN) -Alzheimer's & Dementia, p.4, 2012. ,
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease, New England Journal of Medicine, vol.367, issue.9, pp.795-804, 2012. ,
DOI : 10.1056/NEJMoa1202753
Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis, Obesity Reviews, vol.42, issue.3, pp.204-218, 2008. ,
DOI : 10.1212/WNL.42.3.473
Cholinesterase inhibitors for Alzheimer's disease -The Cockrane Library, 2006. ,
Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease?, Genes, Brain and Behavior, vol.32, issue.2, pp.120-130, 2006. ,
DOI : 10.1016/S0197-4580(89)80005-3
Alzheimer : au-delà de la seule hypothèse cholinergique -Autres systèmes de neurotransmission et modulation des récepteurs nicotiniques -La Lettre du Pharmacologue, 2003. ,
Neuropathological stageing of Alzheimer-related changes, Acta Neuropathologica, vol.80, issue.4, pp.839-859, 1991. ,
DOI : 10.1007/978-3-642-70644-8_2
-Le système nerveux central -Editions Pradel, 2002. ,
Impact of Estrogen Therapy on Alzheimer??s Disease, CNS Drugs, vol.2, issue.4, pp.405-427, 2004. ,
DOI : 10.2165/00023210-200418070-00001
NSAID use does not affect dementia progression or survival in Alzheimer's disease. The Cache County Dementia Progression Study., Alzheimer's & Dementia, vol.7, issue.4, p.367, 2011. ,
DOI : 10.1016/j.jalz.2011.05.1056
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease -Alzheimers Dement, pp.123-131, 2013. ,
-La barrière hémato-encéphalique -Médecine thérapeutique, pp.285-92, 2002. ,
Soigner la maladie d'Alzheimer: Guidance des aidants et relation soignante -Dunod, 2012. ,
Sport et santé: Quelle activité physique pour quelle santé ?-Université de Saint-Etienne, 2005. ,
-Données fondamentales sur les pathologies amyloïde et Tau dans la maladie d'Alzheimer: quelles perspectives thérapeutiques? -Annales Pharmaceutiques Françaises, pp.136-153, 2009. ,
DOI : 10.1016/j.pharma.2009.01.002
Variability in Annual Mini-Mental State Examination Score in Patients With Probable Alzheimer Disease, Archives of Neurology, vol.56, issue.7, pp.857-62, 1999. ,
DOI : 10.1001/archneur.56.7.857
-Tout sur la mémoire -Editions Odile Jacob, 2009. ,
-La maladie d'Alzheimer ? Identifier Comprendre Accompagner -Editions Larousse, 2010. ,
Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials -Alzheimer's & Dementia, pp.263-271, 2006. ,
-Revue Maladie d'Alzheimer : Physiopathologie, Médecine thérapeutique, 1997. ,
Ateliers d'art-thérapie: une nouvelle approche pour les personnes atteintes de la maladie d'Alzheimer et troubles apparentés -Oplinter Kluwer, 2007. ,
Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques, American Journal of Pathology, vol.132, issue.1, pp.86-101, 1988. ,
-A method for estimating progression rates in Alzheimer's disease, Archives of Neurology, vol.58, pp.449-54, 2001. ,
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease, New England Journal of Medicine, vol.369, issue.4, pp.341-350, 2013. ,
DOI : 10.1056/NEJMoa1210951
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS???ADRDA criteria, The Lancet Neurology, vol.6, issue.8, pp.734-780, 2007. ,
DOI : 10.1016/S1474-4422(07)70178-3
Revising the definition of Alzheimer's disease: a new lexicon, The Lancet Neurology, vol.9, issue.11, pp.1118-1145, 2010. ,
DOI : 10.1016/S1474-4422(10)70223-4
-Transgenic mouse models of Alzheimer?s disease: how useful have they been for therapeutic development?, Genomics Proteomics, vol.3, pp.47-59, 2004. ,
Searching for new animal models of Alzheimer's disease - European Journal of Pharmacology, pp.57-63, 2010. ,
-Les troubles précoces de la mémoire épisodique dans la maladie d'Alzheimer -Revue Neurologique, pp.96-101, 2008. ,
Xe Colloque international sur le vieillissement cognitif: 4-5 septembre, 2008. ,
Alzheimer et démences La maladie d'Alzheimer et la mémoire humaine - Revue Neurologique, pp.929-939, 2006. ,
DOI : 10.1016/s0035-3787(06)75102-5
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice, Proceedings of the National Academy of Sciences, pp.1141-1187, 2004. ,
DOI : 10.1001/archpsyc.57.1.95
The Role of Lipid-Lowering Drugs in Cognitive Function: A Meta-Analysis of Observational Studies, Pharmacotherapy, vol.59, issue.6, pp.726-756, 2003. ,
DOI : 10.1016/S0025-7125(02)00008-1
-Projet ETNA3 : évaluer trois thérapeutiques non médicamenteuses dans la maladie d'Alzheimer -Chronisanté, 2012. ,
-Le rôle des ions métalliques dans la maladie d'Alzeimer : apport de la spectroscopie d'absorption X -L'actualité chimique, pp.356-357, 2011. ,
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease -Alzheimers Dement, pp.261-71, 2012. ,
Médicaments de l'Alzheimer -Actualités Pharmaceutiques, pp.43-46, 2008. ,
-Evidence from biomarkers and surrogate endpoints ? NeuroRx, pp.323-353, 2004. ,
DOI : 10.1007/bf03206617
URL : http://europepmc.org/articles/pmc534933?pdf=render
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe, Neurology, vol.74, issue.12, pp.956-64, 2010. ,
DOI : 10.1212/WNL.0b013e3181d6476a
-Effets cardio-vasculaires des inhibiteurs de la cholinestérase dans la maladie d'Alzheimer -Revue Neurologique, pp.968-974, 2007. ,
DOI : 10.1016/s0035-3787(07)92641-7
Global prevalence of dementia, Alzheimer's & Dementia, vol.5, issue.4, pp.2112-2119, 2005. ,
DOI : 10.1016/j.jalz.2009.05.374
-Mieux vivre avec la Maladie d'Alzheimer -Hachette Pratique, 2005. ,
-Traitement symptomatique de la maladie d'Alzheimer et perspectives thérapeutiques ? Thérapie, 2010. ,
DOI : 10.2515/therapie/2010055
Krolak-Salmon P. -Maladie d'Alzheimer et maladies apparentées : vers un diagnostic plus précis et précoce -La Revue de Médecine Interne, pp.846-853, 2010. ,
Imagerie cérébrale et physiopathologie de la maladie d'Alzheimer -Psychologie & NeuroPsychiatrie du vieillissement, pp.269-79, 2007. ,
-Biologie cellulaire UE2 PACES: Manuel, cours + QCM corrigés - Ediscience, 2012. ,
An active and socially integrated lifestyle in late life might protect against dementia, The Lancet Neurology, vol.3, issue.6, pp.343-53, 2004. ,
DOI : 10.1016/S1474-4422(04)00767-7
SGS742: the first GABAB receptor antagonist in clinical trials, Biochemical Pharmacology, vol.68, issue.8, pp.1479-1487, 2004. ,
DOI : 10.1016/j.bcp.2004.07.030
De l'animal expérimental au modèle en recherche biomédicale -Revue philosophique, pp.319-326, 2008. ,
M??mantine (Ebixa??) : une nouvelle strat??gie th??rapeutique dans le traitement des formes mod??r??ment s??v??res ?? s??v??res de la maladie d???Alzheimer, L'Enc??phale, vol.30, issue.1, pp.69-79, 2004. ,
DOI : 10.1016/S0013-7006(04)95418-8
Alzheimer : aspects méthodologiques généraux -Revue Neurologique, pp.261-264, 2004. ,
Clinical diagnostic and management of Alzheimer's disease (3ème edition) -City, 2007. ,
Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease., Proceedings of the National Academy of Sciences, pp.9382-986, 1994. ,
DOI : 10.1073/pnas.91.20.9382
Developing ??-secretase inhibitors for treatment of Alzheimer???s disease, Journal of Neurochemistry, vol.20, pp.71-83, 2012. ,
DOI : 10.1016/j.bmcl.2010.01.005
-Les modèles pharmacologiques dans la recherche sur la maladie d'Alzheimer -Annales Médico-psychologiques, revue psychiatrique, pp.54-62, 2001. ,
DOI : 10.1016/s0003-4487(00)00011-1
Clinical effects of A?? immunization (AN1792) in patients with AD in an interrupted trial, Neurology, vol.64, issue.9, pp.1553-1562, 2005. ,
DOI : 10.1212/01.WNL.0000159740.16984.3C
-La maladie d'Alzheimer -www.sante.gouv.fr, 2000. ,
Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders: Therapeutic potential or a mirage? -Progress in neuropsychopharmacology & biological psychiatry, pp.311347-1355, 2007. ,
-Segregation of missense mutation in the amyloide precursor protein gene with familial Alzheimer's disease ? Nature, p.7046, 1991. ,
SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics, Journal of Neuroimmunology, vol.71, issue.1-2, pp.51-63, 1996. ,
DOI : 10.1016/S0165-5728(96)00130-0
Alzheimer : la stimulation sensorielle comme thérapie -Principes de santé - Thérapies, 2011. ,
A Phase I Study of AIT-082 in Healthy Elderly Volunteers, Journal of Molecular Neuroscience, vol.18, issue.3, pp.283-93, 2002. ,
DOI : 10.1385/JMN:18:3:283
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives, Nature Reviews Drug Discovery, vol.61, issue.7, pp.560-74, 2010. ,
DOI : 10.1038/jcbfm.1988.104
Diseases Biomarkers for Alzheimer's disease therapeutic trials -Progress in Neurobiology, pp.579-593, 2011. ,
Tracking Cognitive Decline in Alzheimers Disease Using the Mini-Mental State Examination: A Meta-Analysis, International Psychogeriatrics, vol.12, issue.2, pp.231-278, 2000. ,
DOI : 10.1017/S1041610200006359
Génétique de la maladie d'Alzheimer -La Revue de Médecine Interne, pp.545-550, 1996. ,
Analyse structurale et fonctionnelle de la préséniline I humaine : implications dans la maladie d'Alzheimer -Thèse de Sciences, 2003. ,
-Alzheimer's Disease: The Challenge of the Second Century -Science Translational Medicine, p.77, 2011. ,
Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3, Journal of Biological Chemistry, vol.270, issue.40, pp.25326-25358, 1997. ,
DOI : 10.1083/jcb.98.3.847
Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases ?-cleavage of amyloid precursor protein and amyloid-? production in vivo, Journal of Neurochemistry, vol.53, issue.3, pp.802-811, 2007. ,
DOI : 10.1358/dof.2006.031.01.957326
Alzheimer : Enjeux scientifiques, médicaux et sociétaux, Les éditions Inserm, 2007. ,
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease, New England Journal of Medicine, vol.345, issue.21, pp.1515-1521, 2001. ,
DOI : 10.1056/NEJMoa010178
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD, Neurology, vol.62, issue.4, pp.591-600, 2004. ,
DOI : 10.1212/01.WNL.0000110315.26026.EF
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade -Lancet Neurologie, pp.119-147, 2010. ,
Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice, Proceedings of the National Academy of Sciences, vol.55, issue.3, pp.13363-13370, 2004. ,
DOI : 10.1002/ana.10853
Maladie d'Alzheimer ? Un coût très élevé pour les familles ,
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis ? Science, pp.486-495, 2003. ,
Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy, Journal of Biological Chemistry, vol.1739, issue.2, pp.1205-1219, 2006. ,
DOI : 10.1016/j.bbadis.2004.06.017
Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-?? in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain, Journal of Neuroscience, vol.25, issue.46, pp.10598-10606, 2005. ,
DOI : 10.1523/JNEUROSCI.2990-05.2005
ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale)--validation of the Slovak version, Bratislava Medical Journal, vol.101, issue.11, pp.598-602, 2000. ,
-Statins and dementia, Current Atherosclerosis Reports, pp.154-161, 2007. ,
Compressing drug development timelines in oncology using phase « 0 » trials -Nature Reviews Cancer, pp.131-140, 2007. ,
-Memantine Une nouvelle option thérapeutique pour combattre la maladie d'Alzheimer ,
-Animal Models of Alzheimer Disease -Cold Spring Harbor Perspectives in Medicine, 2012. ,
-Task-dependent transfer of perceptual to memory representations during delayed spatial frequency discrimination -Vision Research, pp.1759-1769, 2002. ,
-Genetics of Alzheimer's disease: new evidences for an old hypothesis? - Current Opinion in, Genetics & Development, vol.21, issue.3, pp.295-301, 2011. ,
-Translational pharmacology Animal models of Alzheimer's disease and drug development -Drug Discovery Today: Technologies, pp.319-327, 2013. ,
Alzheimer : Comment les industriels du médicament se mobilisent, 2011. ,
In Vivo Structural Studies of the Hippocampus in Normal Aging and in Incipient Alzheimer's Diseasea, Annals of the New York Academy of Sciences, vol.345, issue.1, pp.1-13, 1996. ,
DOI : 10.1016/S0140-6736(95)90265-1
-A familial Alzheimer locus on chromosome 1 ? Science, pp.970-973, 1995. ,
Alzheimer (LECMA)-Cout http ,
Risk Factors for Alzheimer's Disease: A Prospective Analysis from the Canadian Study of Health and Aging, American Journal of Epidemiology, vol.156, issue.5, pp.445-53, 2002. ,
DOI : 10.1093/aje/kwf074
Invertebrate models of Alzheimer's disease, Genes, Brain and Behavior, vol.293, issue.3, pp.147-156, 2005. ,
DOI : 10.1038/35024009
Taurine prevents the neurotoxicity of ??-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer???s disease and other neurological disorders, The FASEB Journal, vol.18, issue.3, pp.511-519, 2004. ,
DOI : 10.1176/ajp.149.2.251
Gene regulation and DNA damage in the ageing human brain ? Nature, pp.883-91, 2004. ,
Lundbeck and Otsuka initiate phase III clinical trials on Lu AE58054 as a new addon treatment for Alzheimer's disease -Corporate release 153, 2013. ,
Mental and Behavioral Disturbances in Dementia: Findings From the Cache County Study on Memory in Aging, American Journal of Psychiatry, vol.157, issue.5, pp.708-722, 2000. ,
DOI : 10.1176/appi.ajp.157.5.708
-Diagnostic biologique de la maladie d'Alzheimer : avancées, limites et perspectives -Revue Neurologique, pp.6-7, 2009. ,
DOI : 10.1016/j.neurol.2008.10.015
-Des archives retrouvées par hasard révèlent les symptômes de la malade Auguste d. première patiente du docteur Alzheimer -La recherche, pp.58-60, 1997. ,
Deficiency, Age and Ageing, vol.23, issue.4, pp.334-341, 1994. ,
DOI : 10.1093/ageing/23.4.334
-Present Imperfect: A Critical Review of Animal Models of the Mnemonic Impairments in Alzheimer's Disease, Neuroscience & Biobehavioral Reviews, vol.22, issue.1, pp.99-120, 1997. ,
Alzheimer's Before It Starts ? Science, pp.790-792, 2012. ,
Earlylife risk factors and the development of Alzheimer's disease ? Neurology, pp.415-435, 2000. ,
A? peptide vaccination prevents memory loss in an animal model of Alzheimer's disease ?Nature, pp.982-985, 2000. ,
Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation, Hippocampus, vol.93, issue.9, pp.844-54, 2009. ,
DOI : 10.1212/WNL.46.2.420
Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis???but what lies beyond?, Biochemical Pharmacology, vol.85, issue.3, pp.289-305, 2013. ,
DOI : 10.1016/j.bcp.2012.11.014
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease, JAMA, vol.283, issue.8, pp.1007-1022, 2000. ,
DOI : 10.1001/jama.283.8.1007
Alzheimer : la construction sociale d'une maladie -Dunod, 2012. ,
DOI : 10.3917/dunod.ngatc.2012.01
Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-??-induced neuronal cell death, Journal of Neurochemistry, vol.67, issue.5, pp.1116-1141, 2009. ,
DOI : 10.1016/S0002-9440(10)63465-7
Amyloid imaging in Alzheimer's disease -Current Opinion in Neurology, pp.398-402, 2007. ,
Maladie d'Alzheimer: De la pathogénie vers des mesures préventives ? -La Revue de Médecine Interne, pp.524-532, 2000. ,
Actualités et perspectives thérapeutiques de la maladie d'Alzheimer -La Revue de Médecine Interne, pp.585-587, 2006. ,
Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles, Neuron, vol.39, issue.3, pp.409-430, 2003. ,
DOI : 10.1016/S0896-6273(03)00434-3
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome ? Neuron, pp.321-353, 2004. ,
Alzheimer et son diagnostic prédémentiel -Neuropsychiatrie : Tendances et, Débats, vol.35, pp.33-42, 2008. ,
Drug development for CNS disorders: strategies for balancing risk and reducing attrition -Nature Reviews Drug Discovery, pp.521-553, 2007. ,
Le dictionnaire impertinent du Futur: Se divertir en découvrant l'avenir et le présent - M21 Editions, 2008. ,
un bon niveau d'études protège contre Alzheimer, 2012. ,
GSK-3?? regulates production of Alzheimer's disease amyloid-?? peptides, Nature, vol.5, issue.6938, pp.435-444, 2003. ,
DOI : 10.1038/nn898
-Iatrogénie et maladie d'Alzheimer -La Revue de Médecine Interne, pp.302-306, 2009. ,
Le système nerveux -www.arsep.org -consulté le 05, 2012. ,
-Les connaissances du pharmacien sur la maladie d'Alzheimer -Actualités pharmaceutiques, pp.9-20, 2009. ,
DOI : 10.1016/s0515-3700(09)70010-2
Alzheimer's Disease, New England Journal of Medicine, vol.362, issue.4, pp.329-344, 2010. ,
DOI : 10.1056/NEJMra0909142
-Prevalence of dementia and Alzheimer's disease among subjects aged 75 years or over: updated results of the PAQUID cohort, Revue neurologique, vol.159, pp.405-411, 2003. ,
-Exploring the Relationship between Alzheimer's Disease Severity and Longitudinal -Costs Value in Health, pp.412-419, 2012. ,
The Alzheimer's Prevention Initiative, Alzheimer's & Dementia, vol.8, issue.4, pp.321-330, 2011. ,
DOI : 10.1016/j.jalz.2012.05.1136
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease ? Neurology, pp.51-56, 1995. ,
-Recherche biomédicale et pratiques cliniques Histoire d'une distinction problématique ? Inserm, 2004. ,
Disease-modifying approaches to Alzheimer???s disease: Challenges and opportunities???Lessons from donepezil therapy, Alzheimer's & Dementia, vol.4, issue.1, pp.109-127, 2008. ,
DOI : 10.1016/j.jalz.2007.11.013
Drug development for Alzheimer's disease: Where are we now and where are we headed?, The American Journal of Geriatric Pharmacotherapy, vol.7, issue.3, pp.167-85, 2009. ,
DOI : 10.1016/j.amjopharm.2009.06.003
-Alzheimer's disease biomarkers: correspondence between human studies and animal models -Neurobiology of Disease, pp.116-146, 2013. ,
Bapineuzumab Phase 3 trials in mild to moderate Alzheimer's disease dementia in apolipoprotein E ?4 carriers (study 302) and non-carriers (Study 301). - Clinical Outcomes ? Clinical Trials in Alzheimer's Disease ? 10, 2012. ,
démence et immigration: Pour une prise en charge adaptée des personnes âgées migrantes en France, Danemark et au Royaume-Uni -L'Harmattan, 2000. ,
-Genes contributing to Alzheimer's disease - Molecular Psychiatry, pp.27-40, 1996. ,
-Drosophila models of neurodegenerative disease ? NeuroRx, pp.438-446, 2005. ,
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease ? Neurology, pp.556-63, 2011. ,
Immunization with amyloid-? attenuates Alzheimer-diseaselike pathology in the PDAPP mouse ? Nature, pp.173-177, 1999. ,
Immunotherapy Reduces Vascular Amyloid-?? in PDAPP Mice, Journal of Neuroscience, vol.28, issue.27, pp.6787-93, 2008. ,
DOI : 10.1523/JNEUROSCI.2377-07.2008
Votre santé par les plantes: Le guide phyto utile pour toute la famille -Alpen Editions, 2005. ,
Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease -Drug Discovery Today, pp.1207-1219, 2001. ,
Alzheimer : Accompagnez votre proche au quotidien -John Libbey Eurotext, 2011. ,
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life -Neurobiology of Disease, pp.293-302, 2009. ,
-Physiologie humaine -Edition de Boeck, 2006. ,
Effects of Ginkgo biloba administered after spatial learning on water maze and radial arm maze performance in young adult rats, Pharmacology Biochemistry and Behavior, vol.84, issue.1, pp.17-25, 2006. ,
DOI : 10.1016/j.pbb.2006.04.003
The molecular genetics of the tauopathies, Experimental Gerontology, vol.35, issue.4, pp.461-471, 2000. ,
DOI : 10.1016/S0531-5565(00)00114-5
-The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease. -Alzheimer's & Dementia, pp.425-451, 2012. ,
Tau protein pathology in neurodegenerative diseases -Trends Neuroscience, pp.428-461, 1998. ,
Update on Elan vaccine for Alzheimer's disease -The Lancet Neurology, p.5, 2004. ,
Transgenic models of Alzheimer???s disease: Learning from animals, NeuroRX, vol.389, issue.3, pp.423-437, 2005. ,
DOI : 10.1038/39321
De l'esprit aux molécules -De Boeck Supérieur, 2002. ,
Molecular biology and genetics of Alzheimer's disease, Comptes Rendus Biologies, vol.328, issue.2, pp.119-130, 2005. ,
DOI : 10.1016/j.crvi.2004.10.013
Pharmacie et surveillance infirmière, 2008. ,
In Vitro Blood-Brain Barrier Models Using Brain Capillary Endothelial Cells Isolated from Neonatal and Adult Rats Retain Age-Related Barrier Properties, PLoS ONE, vol.63, issue.1, 2013. ,
DOI : 10.1371/journal.pone.0055166.g005
Animal models of cognitive dysfunction -Mechanisms of Ageing and Development, pp.100-108, 2006. ,
-Methods of Behavior Analysis in Neuroscience, 2009. ,
Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia -Neuroscience Letters, pp.139-142, 1994. ,
Anne Feltz A. -Physiologie du neurone, 1999. ,
Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention, Progress in Neurobiology, vol.95, issue.4, pp.491-496, 2011. ,
DOI : 10.1016/j.pneurobio.2011.07.004
Conditions de son développement en France, et rôle des mathématiques, 2006. ,
The mouse as a model organism in aging research: Usefulness, pitfalls and possibilities, Ageing Research Reviews, vol.12, issue.1, pp.8-21, 2003. ,
DOI : 10.1016/j.arr.2012.03.010
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid???related disorders, The Lancet Neurology, vol.2, issue.8, pp.482-92, 2003. ,
DOI : 10.1016/S1474-4422(03)00484-8
Current and future therapy in Alzheimer's disease -Fundamental & Clinical Pharmacology, pp.265-274, 2008. ,
Designing drug trials for Alzheimer???s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force, Alzheimer's & Dementia, vol.9, issue.4, pp.438-482, 2013. ,
DOI : 10.1016/j.jalz.2013.03.007
Facteurs de risque de la maladie d'Alzheimer: vers une prévention? -La Presse Médicale, pp.1309-1316, 2006. ,
DOI : 10.1016/s0755-4982(06)74810-2
Naturally secreted oligomers of amyloid ?? protein potently inhibit hippocampal long-term potentiation in vivo, Nature, vol.36, issue.6880, pp.535-539, 2002. ,
DOI : 10.1021/jm00054a014
Toward a theory of episodic memory: The frontal lobes and autonoetic consciousness., Psychological Bulletin, vol.121, issue.3, pp.331-354, 1997. ,
DOI : 10.1037/0033-2909.121.3.331
Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia, The World Journal of Biological Psychiatry, vol.70, issue.2, pp.69-84, 2005. ,
DOI : 10.1136/jnnp.70.2.229
Alzheimer's Disease International. The Global Economic Impact of Dementia - World Alzheimer Report, 2010. ,
The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project, International Journal of Geriatric Psychiatry, vol.20, issue.(Suppl 1), pp.825-832, 2011. ,
DOI : 10.1002/gps.1332
-Vaccination as a therapeutic approach to Alzheimer'Disease - Journal of medicine, pp.17-31, 2010. ,
-The older rabbit as an animal model: implications for Alzheimer's disease -Neurobiology of Aging, pp.283-290, 1996. ,
Binding of Congo Red to Amyloid Protofibrils of the Alzheimer A??9???40 Peptide Probed by Molecular Dynamics Simulations, Biophysical Journal, vol.103, issue.3, pp.550-557, 2012. ,
DOI : 10.1016/j.bpj.2012.07.008
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs -Pharmacology & Therapeutics, pp.93-113, 2000. ,